The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial
暂无分享,去创建一个
Akshay S. Desai | S. Solomon | S. Colan | A. Desai | J. McMurray | E. Braunwald | S. Lipshultz | C. Macrae | A. Cirino | Carolyn Y. Ho | S. Day | J. Orav | Allison L. Cirino | Ling Shi | L. Shi | Ling Shi | S. Day
[1] M. Konstam,et al. Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials , 2016, Circulation. Heart failure.
[2] Daniel G. MacArthur,et al. The ExAC browser: displaying reference data information from over 60 000 exomes , 2016, bioRxiv.
[3] Akshay S. Desai,et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial , 2016, The Lancet.
[4] Ricardo Villamarín-Salomón,et al. ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..
[5] O. Havndrup,et al. Efficacy and safety of the angiotensin II receptor blocker losartan for hypertrophic cardiomyopathy: the INHERIT randomised, double-blind, placebo-controlled trial. , 2015, The lancet. Diabetes & endocrinology.
[6] E. Antman,et al. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression. , 2015, JACC. Heart failure.
[7] Matthew S. Lebo,et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity , 2015, Genetics in Medicine.
[8] Bale,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[9] G. Felker,et al. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). , 2014, JACC. Heart failure.
[10] S. Abbara,et al. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy. , 2013, JACC. Heart failure.
[11] R. Kwong,et al. T1 Measurements Identify Extracellular Volume Expansion in Hypertrophic Cardiomyopathy Sarcomere Mutation Carriers With and Without Left Ventricular Hypertrophy , 2013, Circulation. Cardiovascular imaging.
[12] G. Koch,et al. Evaluating Treatment Efficacy by Multiple End Points in Phase II Acute Heart Failure Clinical Trials: Analyzing Data Using a Global Method , 2012, Circulation. Heart failure.
[13] Barry J Maron,et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.
[14] R. Foley,et al. Kidney function reference values in US adolescents: National Health And Nutrition Examination Survey 1999-2008. , 2011, Clinical journal of the American Society of Nephrology : CJASN.
[15] J. Seidman,et al. Identifying sarcomere gene mutations in hypertrophic cardiomyopathy: a personal history. , 2011, Circulation research.
[16] Barry J Maron,et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Journal of the American College of Cardiology.
[17] Roger R Markwald,et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-β. , 2010, The Journal of clinical investigation.
[18] S. Colan,et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. , 2010, The New England journal of medicine.
[19] Arantxa González,et al. Circulating Biomarkers of Collagen Metabolism in Cardiac Diseases , 2010, Circulation.
[20] B. Maron,et al. Echocardiographic Strain Imaging to Assess Early and Late Consequences of Sarcomere Mutations in Hypertrophic Cardiomyopathy , 2009, Circulation. Cardiovascular genetics.
[21] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[22] M. Penicka,et al. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. , 2009, The Journal of molecular diagnostics : JMD.
[23] K. Ohtomo,et al. A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an Angiotensin II receptor blocker. , 2007, International heart journal.
[24] G. Church,et al. Polony Multiplex Analysis of Gene Expression (PMAGE) in Mouse Hypertrophic Cardiomyopathy , 2007, Science.
[25] Marc K. Halushka,et al. Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome , 2006, Science.
[26] C. Mady,et al. Effect of Losartan on left ventricular diastolic function in patients with nonobstructive hypertrophic cardiomyopathy. , 2005, The American journal of cardiology.
[27] J. Varni,et al. The PedsQL™ as a pediatric patient-reported outcome: reliability and validity of the PedsQL™ Measurement Model in 25,000 children , 2005, Expert review of pharmacoeconomics & outcomes research.
[28] S. Seto,et al. Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. , 2005, Circulation journal : official journal of the Japanese Circulation Society.
[29] C. Tracy,et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice G , 2003, European heart journal.
[30] B. Maron,et al. Clinical course of hypertrophic cardiomyopathy with survival to advanced age. , 2003, Journal of the American College of Cardiology.
[31] B. Maron. Sudden death in young athletes. , 1980, The New England journal of medicine.
[33] J. Gardin,et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.